In adults with t(8;21)AML, posttransplant RUNX1/RUNX1T1-based MRD monitoring, rather than c-KIT mutations, allows further risk stratification-Reference-Cited by-同舟云学术

In adults with t(8;21)AML, posttransplant RUNX1/RUNX1T1-based MRD monitoring, rather than c-KIT mutations, allows further risk stratification

Published:2014-09-18 Issue:12 Volume:124 Page:1880-1886
ISSN:0006-4971
Container-title:Blood
language:en
Short-container-title:

Author:

Wang Yu¹,Wu De-Pei²,Liu Qi-Fa³,Qin Ya-Zhen¹,Wang Jing-Bo⁴,Xu Lan-Ping¹,Liu Yan-Rong¹,Zhu Hong-Hu¹,Chen Jia²,Dai Min³,Huang Xiao-Jun¹⁵

Affiliation:

1. Peking University People’s Hospital, Peking University Institute of Hematology, Beijing Key Laboratory of Hematopoietic Stem Cell Transplantation, Beijing, China;

2. The First Affiliated Hospital of Soochow University, Suzhou, Jiangsu, China;

3. Nanfang Hospital, Nanfang Medical University, Guangzhou, Guangdong, China;

4. Aero Center Space Hospital, Beijing, China; and

5. Peking-Tsinghua Center for Life Sciences, Beijing, China

Abstract

Key Points RUNX1/RUNX1T1-based MRD status at 1, 2, and 3 months after HSCT could discriminate patients at high risk of post-HSCT relapse. Rather than c-KIT mutations, MRD monitoring allows further rapid identification of patients at high risk of relapse after allo-HSCT.

Publisher

American Society of Hematology

Subject

Cell Biology,Hematology,Immunology,Biochemistry

Link

http://ashpublications.org/blood/article-pdf/124/12/1880/1379510/1880.pdf

Reference24 articles.

1. A white blood cell index as the main prognostic factor in t(8;21) acute myeloid leukemia (AML): a survey of 161 cases from the French AML Intergroup.;Nguyen;Blood,2002

2. Individual patient data-based meta-analysis of patients aged 16 to 60 years with core binding factor acute myeloid leukemia: a survey of the German Acute Myeloid Leukemia Intergroup.;Schlenk;J Clin Oncol,2004

3. Prognostic factors and outcome of core binding factor acute myeloid leukemia patients with t(8;21) differ from those of patients with inv(16): a Cancer and Leukemia Group B study.;Marcucci;J Clin Oncol,2005

4. The clinical spectrum of adult acute myeloid leukaemia associated with core binding factor translocations.;Appelbaum;Br J Haematol,2006

5. Hematopoietic stem cell transplantation for core binding factor acute myeloid leukemia: t(8;21) and inv(16) represent different clinical outcomes.;Kuwatsuka;Blood,2009

Cited by 105 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Measurable residual disease (MRD)-testing in haematological cancers: A giant leap forward or sideways?;Blood Reviews;2024-08

2. Single-cell immune landscape of measurable residual disease in acute myeloid leukemia;Science China Life Sciences;2024-07-19

3. Allogeneic transplantation for AML with RUNX1::RUNX1T1 fusion: a time-dependent analysis in a retrospective study;2024-07-12

4. Neratinib impairs function of m6A recognition on AML1-ETO pre-mRNA and induces differentiation of t (8;21) AML cells by targeting HNRNPA3;Cancer Letters;2024-07

5. Prophylactic therapy using epigenetic agents for RUNX1::RUNXT1-positive high-risk AML after Allo-HSCT;Annals of Hematology;2024-06-22